Compare PTON & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTON | BEAM |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2019 | 2019 |
| Metric | PTON | BEAM |
|---|---|---|
| Price | $6.10 | $27.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $7.89 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 9.0M | 2.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.13 | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.44 | $33.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $3.65 | $15.60 |
| 52 Week High | $9.20 | $38.26 |
| Indicator | PTON | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 34.36 |
| Support Level | $5.96 | $26.96 |
| Resistance Level | $6.96 | $29.68 |
| Average True Range (ATR) | 0.24 | 2.45 |
| MACD | 0.04 | -0.95 |
| Stochastic Oscillator | 66.48 | 5.82 |
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.